Vaccine (DNA plasmid) · Immune activation, directed at HIV-1 Gag and HIV-1 Pol
Phase 1/2Most advanced trial (none active)
What is INO-6145?
INO-6145 is a DNA vaccine consisting of circular, double-stranded plasmids encoding synthetic HIV-1 multiclade consensus Gag and Pol proteins. It is designed to activate immune responses against HIV-1 and is studied in HIV-1 infection.
Summary written with AI from the sources listed at the end of this page.
At a glance
Drug type
Vaccine (DNA plasmid)
Targets
HIV-1 Gag (antigen), HIV-1 Pol (antigen)
Mechanism
Immune activation, directed at HIV-1 Gag and HIV-1 Pol
Therapy area
Infectious disease
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.